Unwinding the loop of Bcl-2 phosphorylation

Leukemia

Volumn 15, Issue 6, 2001, Pages 869-874

  Blagosklonny, M V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bcl 2; Microtubule active drugs; Mitosis; Paclitaxel

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; PACLITAXEL; PROTEIN BCL 2; PROTEIN KINASE; SERINE; THREONINE;

APOPTOSIS; CELL DEATH; CELL LINE; CELL NUCLEUS MEMBRANE; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; MICROTUBULE; MITOGENESIS; MITOSIS INHIBITION; MODEL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034988898     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402134     Document Type: Review

References (88)

1. A day in the life of the Bcl-2 protein: Does the turnover rate of Bcl-2 serve as a biological clock for cellular lifespan regulation?
2. Double identity for proteins of the Bcl-2 family
3. BCL-2 family: Regulators of cell death
4. Bcl-2 proteins: Regulators of apoptosis or of mitochondrial homeostasis?
5. Inactivation of Bcl-2 by phosphorylation
6. Bcl-2 is phosphorylated and inactivated by ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M
7. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway
8. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of Bcl-2 in association with suppression of apoptosis
9. Bcl-2 phosphorylation required for anti-apoptosis function
10. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy
11. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein
12. Raf1/bcl2 phosphorylation: A step from microtubule damage to cell death
13. Bcl2 is the guardian of microtubule integrity
14. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest
15. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis
16. Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2
17. Apoptosis: Cell death defined by caspase activation
18. Caspases and apoptosis - Biology and terminology
19. Cell death beyond apoptosis
20. More than one way to go
21. Mitochondria and apoptosis
22. BCL-2 family members and the mitochondria in apoptosis
23. Investigations of the subcellular distribution of the Bcl-2 protein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane
24. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells
25. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human AML HL-60 cells
26. Temporal relationship of CDK1 activation and mitotic arrest to cytosolic acumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells
27. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase
28. The p53-binding protein 53BP2 also interacts with Bcl2 and impedes cell cycle progression at G2/M
29. 'Loop' domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis
30. Microtubule-damaging drugs triggered Bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of Bcl2 protein
31. Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells
32. Interleukin-3 induces the phosphorylation of a distinct fraction of bcl-2
33. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis
34. Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: Suppression of apoptosis with concomitant cell proliferation
35. The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2
36. Association of insulin receptor substrate proteins with Bcl-2 and their effects on its phosphorylation and antiapoptotic function
37. Checkpoints controlling mitosis
38. A novel pool of protein phosphatase 2A is associated with microtubules and is regulated during the cell cycle
39. Distinct roles of PP1 and PP2A-like phosphatases in control of microtubule dynamics during mitosis
40. Okadaic acid induces interphase to mitotic-like microtubule dynamic instability by inactivation rescue
41. Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation
42. Molecular effects of paclitaxel: Myths and reality
43. Repression of TFIIH transcriptional activity and TFIIH-associated cdk7 kinase activity at mitosis
44. Ability of the c-mos product to associate with and phosphorylate tubulin
45. Association of mitogen-activated protein kinase with the microtubule cytoskeleton
46. Control of microtubule dynamics by oncoprotein 18: Dissection of the regulatory role of multisite phosphorylation during mitosis
47. Serine/threonine phosphorylation in cytokine signal transduction
48. Activated Raf induces the hyperphosphorylation of Stathmin and the reorganization of the microtubule network
49. Characterization of Raf-1 activation in mitosis
50. Mechanisms of Taxol-induced cell death are concentration dependent
51. Mitotic Raf-1 is stimulated independently of Ras and is active in the cytoplasm
52. Vinblastine-induced phosphorylation of bcl-2 and bcl-XL is mediated by JNK and occurs in parallel with inactivation of the raf-1/MEK/ERK cascade
53. Uncoupling Raf1 from MEk1/2 impairs only a subset of cellular responses to Raf activation
54. Further characterization of the c-mos transcript and its cell cycle specific expression in NIH3T3 cells
55. Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells
56. Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability
57. Raf-1 protein kinase is important for progesterone-induced Xenopus oocyte maturation and acts downstream of mos
58. c-Jun N-terminal kinase activation in Xenopus laevis eggs and embryos: A possible non-genomic role for the JNK signaling pathway
59. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases
60. Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells
61. Regulation of Bcl2 phosphorylation by stress response kinase pathway
62. Transient stimulation of the c-Jun-NH2-terminal kinase/Activator Protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts
63. Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells
64. Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL
65. MEK inhibition enhances paclitaxel-induced tumor apoptosis
66. Bcl-xL is phosphorylated in malignant cells following microtubule disruption
67. Depletion of ErbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity
68. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1
69. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathway
70. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells
71. p53 mediates bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway
72. Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells
73. Synergy between Raf and BCL2 in abrogating dependency of hematopoietic cells
74. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)
75. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD
76. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt
77. Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition
78. Phosphorylation of Bcl-2 after exposure of human leukemic cells to retinoic acid
79. Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation
80. A node between proliferation, apoptosis, and growth arrest
81. Apoptosis in different stages of human oogenesis
82. Targeted gene disruption of Hsp70-2 results in failed meiosis, germ cell apoptosis, and male infertility
83. 30 KDa phosphorylated form of Bcl-2 protein in human colon
84. Apoptotic pathways: Paper wraps stone blunts scissors
85. The most unkindest cut of all: On the multiple roles of mammalian caspases
86. Genetic analysis of chemo-resistance in primary murine lymphomas
87. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL
88. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3